Some cancer medicines lower the potassium or phosphate in the blood. A mild fall usually causes no symptoms, so it is found on blood tests and treated with tablets or a drip. The medicine is paused only when a low level is severe or does not respond. Tell your team about muscle weakness, cramps or pain, palpitations, or diarrhoea or vomiting. Your own team's plan comes first.
Four medicines are covered from their own labels, US and EU side by side (dinutuximab in the US, dinutuximab beta in the EU); the general correction steps come from UK and society sources written for adults in general. Local protocols come first.
Quizartinib: the potassium rule is tied to the QT interval. Both labels ask for hypokalaemia and hypomagnesaemia to be monitored and corrected before and during treatment, more often with diarrhoea or vomiting. The US label alone contraindicates quizartinib in severe hypokalaemia and has a row for Grade 3 or 4 hypokalaemia (below 3 mmol/L): interrupt, correct according to institutional guidelines, and restart at the previous dose at Grade 2 or less without symptoms. The EU SmPC has neither; it reports two cardiac arrests, both in the setting of severe hypokalaemia. ECG and QTcF rules are on the QT protocol.
Nirogacestat: monitor phosphate and potassium regularly and supplement as necessary (both labels). Withhold, then restart at 100 mg twice daily once Grade 1 or less or baseline: in the US for Grade 3 or 4 hypophosphataemia persisting for 3 days or more despite maximal replacement, in the EU for Grade 3 persisting for 7 days or more; for hypokalaemia despite maximal replacement, Grades 3 or 4 in the US and Grade 3 of any duration in the EU.
Dinutuximab: the US label asks for serum electrolytes daily during therapy (severe hypokalaemia in 37% in its trial); the EU SmPC for dinutuximab beta recommends regular monitoring. Neither gives a potassium dose rule.
Abiraterone: correct hypokalaemia before and during treatment and check potassium at least monthly (US), or monthly and every 2 weeks for 3 months in people at significant risk of congestive heart failure (EU). Only the EU SmPC says to consider keeping potassium at 4.0 mM or above in people with hypokalaemia and to withhold for Grade 3 or higher.
Lutetium-177 dotatate is not covered: both labels list hypokalaemia and neither gives a rule for it. The one potassium rule, in the EU SmPC, concerns a high potassium from the amino acid infusion (see gaps).
Replacement: oral potassium for mild or moderate hypokalaemia and intravenous potassium chloride in hospital for severe or symptomatic hypokalaemia (NHS SPS, England); the 2014 SEOM guideline likewise gives potassium by mouth for mild and moderate and into a vein for severe hypokalaemia (level IV, grade D). The KDIGO conference participants think an ECG and magnesium should be checked. Sources differ on infusion rates. For phosphate there is no agreed guidance: the UK Q&A replaces below 0.3 mmol/L and considers it at 0.3 to 0.6 mmol/L, while a nephrology review says to correct low phosphate in people with cancer when it is first recognised.
Why: Both the US label and the EU SmPC ask for this, because quizartinib lengthens the QT interval. Both also ask for electrolytes and ECGs to be checked more often in people who have diarrhoea or vomiting. The abiraterone labels likewise ask for low potassium to be corrected before treatment starts.
“Perform an ECG and correct electrolyte abnormalities prior to initiation of treatment with VANFLYTA.”
Why: This is a contraindication in the US label. The EU SmPC does not list it among its contraindications, but reports that two patients had a cardiac arrest with ventricular fibrillation, one fatal, both in the setting of severe hypokalaemia.
“VANFLYTA is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or in patients with a history of ventricular arrhythmias or torsades de pointes”
Why: In the label's main trial, severe low potassium occurred in 37% of patients given dinutuximab against 2% of those not given it, and severe low sodium in 23% against 4%. The EU SmPC for dinutuximab beta says only that regular monitoring of electrolytes is recommended. Neither gives a dose rule for low potassium.
“Monitor serum electrolytes daily during therapy with Unituxin.”
Why: Both labels say this in nearly the same words and neither gives an interval. The US label reports decreased phosphate in 65% and decreased potassium in 22% of people on nirogacestat in its trial; the EU SmPC reports a median of 15 days to the first low phosphate or low potassium.
“Monitor phosphate and potassium levels regularly and supplement as necessary.”
Why: The US label explains that abiraterone can cause high blood pressure, low potassium and fluid retention through raised mineralocorticoid levels, and that QT prolongation and torsades de pointes have been seen in people who became hypokalaemic on it. The EU SmPC says monthly, and every 2 weeks for the first 3 months in people at significant risk of congestive heart failure.
“Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month.”
Why: The KDIGO conference lists these as what its participants think a management protocol should include; it is a conference view, not a graded recommendation. NHS SPS says to identify and treat the underlying causes and names magnesium depletion, diarrhoea and medicines among them. NHS Grampian notes that potassium can be difficult to correct until magnesium is normal.
“ECG and magnesium should be checked.”
Why: This is NHS SPS guidance for adults in England, which gives 24 mmol up to 2 to 3 times a day for mild and 24 to 36 mmol up to 3 to 4 times a day for moderate hypokalaemia, with lower doses possibly needed in renal impairment. The KDIGO report says oral supplements are safe and generally preferred to intravenous replacement in noncritical scenarios.
“Use oral potassium replacement.”
Why: NHS SPS says potassium overdose can be fatal and that intravenous potassium should be given where appropriate monitoring is available. It gives an initial 40 mmol/L, a rate that should not normally exceed 10 mmol an hour, and cardiac monitoring above 20 mmol an hour. Other sources allow different rates (see variants).
“IV potassium chloride should be given in a hospital setting.”
Why: This row is in the US label only, and the label leaves the method of correction to institutional guidelines. The EU SmPC has no row for hypokalaemia: it asks for monitoring and correction, and its general row for Grade 3 or 4 non-haematological reactions interrupts quizartinib.
“Interrupt VANFLYTA. Correct hypokalemia and hypomagnesemia according to institutional guidelines. VANFLYTA may be restarted at the previous dose when the adverse reaction improves to Grade 2 or less without symptoms.”
Why: The two labels set different waiting times and neither gives a reason. The US label notes that CTCAE version 5.0 has no numeric thresholds for grading low phosphate. In CTCAE itself, Grade 3 is severe or medically significant but not immediately life-threatening, with hospitalisation indicated.
“Withhold OGSIVEO until resolved to Grade ≤ 1 or baseline, then restart at a dosage of 100 mg twice daily.”
Why: Both labels hold the medicine only after maximal replacement has failed. CTCAE Grade 3 hypokalaemia is potassium below 3.0 down to 2.5 mmol/L with hospitalisation indicated.
“For Grade 3 hypokalaemia of any duration, despite maximal replacement therapy, nirogacestat should be withheld until resolved to Grade ≤ 1 or baseline, then it should be restarted at a dose of 100 mg twice daily”
Why: This is the approach of a nephrology review of low phosphate in people with cancer, which names antacids and diarrhoea as examples of causes that can be dealt with. The same review says low phosphate, unless recurrent and life-threatening, should not be regarded as a reason to discontinue active cancer therapy. It is a review, not a guideline.
“The general approach to hypophosphatemia should be to treat the underlying cause.”
Clinical Kidney Journal (Adhikari et al.; narrative review, no conflict of interest declared) 2021
Why: This is the UK Medicines Information answer for adults, based on one hospital trust's practice; it says there are no national guidelines and practice varies. It replaces phosphate below 0.3 mmol/L and considers it at 0.3 to 0.6 mmol/L if the person has symptoms or after weighing risks and benefits; its main text says intravenous therapy is indicated for severe or symptomatic low phosphate, and its summary says it may be considered. The 2025 umbrella review found the general consensus is to treat severe or moderate symptomatic low phosphate, with differing recommendations on dose.
“In severe hypophosphataemia, in symptomatic patients and when the oral route is not appropriate, intravenous phosphate therapy may be considered.”
UK Medicines Information (NHS), copy hosted by Gloucestershire Hospitals NHS Foundation Trust 2017
Why: The UK answer says calcium may fall further when phosphate is replaced, and that phosphate is cleared by the kidneys.
“Patients with hypocalcaemia should have their calcium corrected before replacing phosphate to prevent further hypocalcaemia.”
UK Medicines Information (NHS), copy hosted by Gloucestershire Hospitals NHS Foundation Trust 2017
Why: Both points are in the EU SmPC only. The US label says to correct hypokalaemia before and during treatment and gives no level and no hold. A review of electrolyte disorders says the low potassium is managed by the low-dose prednisone given with abiraterone, potassium chloride supplements and/or a mineralocorticoid antagonist.
“For patients who develop Grade ≥ 3 toxicities including hypertension, hypokalaemia, oedema and other non-mineralocorticoid toxicities, treatment should be withheld and appropriate medical management should be instituted.”
Why: This is the counselling the US nirogacestat label asks for. The dinutuximab label asks carers to report seizures, heart palpitations and muscle cramping; the US abiraterone patient information lists dizziness, fast or irregular heartbeats, feeling faint or lightheaded and muscle weakness, among other symptoms; the quizartinib Medication Guide adds diarrhoea or vomiting.
“Advise patients that they will be monitored for these and to contact their healthcare provider if they experience muscle pain or weakness”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
No graded guideline covers low potassium or low phosphate caused by these medicines. The product labels are the source for monitoring and dose holds, and the US and EU texts differ for quizartinib (a contraindication and a hypokalaemia row in the US only), nirogacestat (low phosphate persisting for 3 days or more at Grades 3 or 4 in the US, for 7 days or more at Grade 3 in the EU) and abiraterone (a hold for Grade 3 or higher and a potassium level of 4.0 mM or above to consider, in the EU only). For correcting low potassium, the only graded source read is the 2014 SEOM guideline, which gives all its potassium recommendations level of evidence IV and grade of recommendation D. NHS SPS (2024) is the current national guidance for adults in England and is ungraded. The KDIGO conference report (2020, supported in part by unrestricted educational grants from six companies) says oral supplements are generally preferred in noncritical scenarios, that treatment thresholds have not been defined, and that it did not address emergency management. For low phosphate there is no agreed guidance: the UK Medicines Information answer (2017) and a 2025 umbrella review of 33 publications both say so. The UK answer treats below 0.3 mmol/L and considers treatment at 0.3 to 0.6 mmol/L; a 2021 nephrology review says low phosphate in people with cancer should be corrected when it is first recognised. Both positions are shown.
Daiichi Sankyo (FDA label, DailyMed) 2026 · European Medicines Agency (product information) 2026 · SpringWorks Therapeutics (FDA label, DailyMed) 2026 · European Medicines Agency (product information; marketing authorisation holder Merck Europe B.V.) 2026 · Janssen (FDA label, DailyMed) 2024 · European Medicines Agency (product information) 2024 · Sociedad Española de Oncología Médica (Clinical and Translational Oncology; De las Peñas et al.; two authors declare being scientific advisors of Otsuka, Spain) 2014 · NHS Specialist Pharmacy Service (England) 2024 · KDIGO (Kidney International; Clase et al.) 2020 · UK Medicines Information (NHS), copy hosted by Gloucestershire Hospitals NHS Foundation Trust 2017 · BMC Medicine (Netzer et al.; funded by the University of Bern and its hospital, with a Swiss National Foundation grant to one author, no competing interests declared) 2025 · Clinical Kidney Journal (Adhikari et al.; narrative review, no conflict of interest declared) 2021
Where it differs: The US label contraindicates quizartinib in severe hypokalaemia or severe hypomagnesaemia and has a dose-modification row for Grade 3 or 4 hypokalaemia (below 3 mmol/L) or hypomagnesaemia: interrupt, correct according to institutional guidelines, restart at the previous dose at Grade 2 or less without symptoms. The EU SmPC lists hypersensitivity, congenital long QT syndrome and breast-feeding as contraindications and has no hypokalaemia row; it says electrolytes should be maintained in the normal range and that monitoring and correction of hypokalaemia and hypomagnesaemia should be performed prior to and during treatment.
Evidence: Regulatory labels. The US label reports potassium decreased in 59% of people on quizartinib with chemotherapy (Grade 3 or 4 in 22%) and 56% on placebo with chemotherapy (18%). The EU SmPC reports two cardiac arrests with ventricular fibrillation, one fatal, both in the setting of severe hypokalaemia.
Daiichi Sankyo (FDA label, DailyMed) 2026 · European Medicines Agency (product information) 2026
Where it differs: Low phosphate: the US label withholds for Grades 3 or 4 persisting for 3 days or more despite maximal replacement therapy; the EU SmPC for Grade 3 persisting for 7 days or more. Low potassium: the US label withholds for Grades 3 or 4 despite maximal replacement therapy; the EU SmPC for Grade 3 of any duration despite maximal replacement therapy. Both restart at 100 mg twice daily after recovery to Grade 1 or less or baseline.
Evidence: Regulatory labels, both from the DeFi trial. The US label reports decreased phosphate in 65% on nirogacestat and 11% on placebo, phosphate below 2 mg/dL in 20%, decreased potassium in 22% and 4.2%, and Grade 3 decreased potassium in 1.4%. The EU SmPC reports hypophosphataemia in 43% and hypokalaemia in 12%, against 7% and 1% on placebo, and Grade 3 events of hypophosphataemia and hypokalaemia in 3% (printed as one figure for the two).
SpringWorks Therapeutics (FDA label, DailyMed) 2026 · European Medicines Agency (product information; marketing authorisation holder Merck Europe B.V.) 2026
Where it differs: The US label asks for monitoring at least once a month and for hypokalaemia to be corrected before and during treatment. The EU SmPC asks for monthly monitoring, every 2 weeks for the first three months in people at significant risk of congestive heart failure, says to consider maintaining potassium at 4.0 mM or above in people with pre-existing or new hypokalaemia, and withholds treatment for Grade 3 or higher toxicities including hypokalaemia until they resolve to Grade 1 or baseline.
Evidence: Regulatory labels. The US label reports grades 3 to 4 hypokalaemia in 4% on abiraterone and 2% on placebo in four pooled trials using prednisone 5 mg twice daily, and in 10% and 1% in LATITUDE, which used prednisone 5 mg daily. The EU patient leaflet tells patients to stop abiraterone and see a doctor immediately for muscle weakness, muscle twitches or palpitations.
Janssen (FDA label, DailyMed) 2024 · European Medicines Agency (product information) 2024
Where it differs: NHS SPS (England, 2024): the rate should not normally exceed 10 mmol an hour, rates above 20 mmol an hour require cardiac monitoring, and no more than 40 mmol/L through a peripheral line. NHS Grampian (local policy, version 5, 2025): a maximum of 10 mmol an hour for potassium of 2.5 to 3.5 mmol/L and 20 mmol an hour below 2.5 mmol/L, with continuous ECG monitoring mandatory at 20 mmol an hour and at concentrations of 40 mmol in 500 mL or higher. KDIGO conference report (2020): intravenous potassium chloride at a rate up to 20 mmol an hour can be a safe alternative in severe hypokalaemia and when oral intake is not possible. SEOM (Spain, 2014): for severe hypokalaemia the rate should not exceed 20 an hour (printed as "20 Eq/h", with 100 to 150 mEq a day in brackets; the unit is as printed and is read here as mEq, which for potassium equals mmol) and the concentration 30 mEq in each 500 cc.
Evidence: SEOM grades its potassium recommendations level of evidence IV, grade of recommendation D. SPS, NHS Grampian and the KDIGO report are ungraded. The KDIGO report notes that high concentrations given peripherally can cause pain or sclerosis.
NHS Specialist Pharmacy Service (England) 2024 · NHS Grampian (local policy) 2025 · KDIGO (Kidney International; Clase et al.) 2020 · Sociedad Española de Oncología Médica (Clinical and Translational Oncology; De las Peñas et al.; two authors declare being scientific advisors of Otsuka, Spain) 2014
Where it differs: NHS SPS: 24 mmol up to 2 to 3 times a day for mild hypokalaemia (3.0 to 3.5 mmol/L) and 24 to 36 mmol up to 3 to 4 times a day for moderate (2.5 to 2.9 mmol/L). NHS Grampian: two effervescent tablets three times a day (72 mmol a day) at 3.0 to 3.4 mmol/L, three tablets three times a day (108 mmol a day) at 2.5 to 2.9 mmol/L, and says intravenous supplementation is usually required below 3 mmol/L. SEOM: foods rich in potassium or 40 to 100 mmol a day by mouth for mild hypokalaemia (3 to 3.5 mmol/L) and oral potassium for moderate hypokalaemia, which it prints as 2 to 3 mmol/L although its severe band, treated intravenously, is below 2.5 mmol/L; the two bands overlap and the guideline does not resolve it.
Evidence: National guidance (SPS), a local policy (NHS Grampian) and a society guideline (SEOM, level IV, grade D). None is specific to cancer medicines.
NHS Specialist Pharmacy Service (England) 2024 · NHS Grampian (local policy) 2025 · Sociedad Española de Oncología Médica (Clinical and Translational Oncology; De las Peñas et al.; two authors declare being scientific advisors of Otsuka, Spain) 2014
Where it differs: UK Medicines Information Q&A (2017, reflecting practice at Leeds Teaching Hospitals): replace below 0.3 mmol/L; at 0.3 to 0.6 mmol/L consider replacement if the person has symptoms or after weighing risks and benefits; oral phosphate 1 to 2 effervescent tablets three times a day; intravenous regimens of 0.2 to 0.5 mmol/kg a day up to a maximum of 50 mmol. Adhikari 2021 (nephrology review): low phosphate in people with cancer should be corrected when it is first recognised, with diet first, then oral phosphate, and parenteral replacement where the gut cannot be used. Umbrella review 2025: no clear consensus on when and how to supplement.
Evidence: No graded recommendation. The umbrella review included 33 publications (11 guidelines, 19 reviews, 3 consensus statements), and it found no recommendations on when to test for low phosphate with tyrosine kinase inhibitors.
UK Medicines Information (NHS), copy hosted by Gloucestershire Hospitals NHS Foundation Trust 2017 · Clinical Kidney Journal (Adhikari et al.; narrative review, no conflict of interest declared) 2021 · BMC Medicine (Netzer et al.; funded by the University of Bern and its hospital, with a Swiss National Foundation grant to one author, no competing interests declared) 2025
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Quizartinib: monitor and correct hypokalaemia and hypomagnesaemia before and during treatment, more often with diarrhoea or vomiting (US) “Monitor and correct hypokalemia and hypomagnesemia prior to and during treatment with VANFLYTA. Maintain electrolytes in the normal range. Monitor electrolytes and ECGs more frequently in patients who experience diarrhea or vomiting.” | Regulatory label; not graded | Daiichi Sankyo (FDA label, DailyMed) 2026 |
| Quizartinib: the same monitoring in the EU SmPC “Monitoring and correction of hypokalaemia and hypomagnesaemia should be performed prior to and during treatment with VANFLYTA.” | Regulatory label; not graded | European Medicines Agency (product information) 2026 |
| Quizartinib: cardiac arrests in the setting of severe hypokalaemia (EU SmPC) “experienced cardiac arrest with recorded ventricular fibrillation, one with a fatal outcome, both in the setting of severe hypokalaemia” | Regulatory label; not graded | European Medicines Agency (product information) 2026 |
| Nirogacestat: Grade 3 low phosphate for 7 days or more despite maximal replacement, withhold (EU SmPC) “For Grade 3 hypophosphataemia persisting for ≥ 7 days despite maximal replacement therapy, nirogacestat should be withheld until resolved to Grade ≤ 1 or baseline, then it should be restarted at a dose of 100 mg twice daily” | Regulatory label; not graded | European Medicines Agency (product information; marketing authorisation holder Merck Europe B.V.) 2026 |
| Nirogacestat: Grades 3 or 4 low phosphate for 3 days or more despite maximal replacement, withhold (US label) “Hypophosphatemia persisting for ≥ 3 days despite maximal replacement therapy” | Regulatory label; not graded | SpringWorks Therapeutics (FDA label, DailyMed) 2026 |
| Nirogacestat: how low phosphate was graded in the US label “CTCAE Version 5.0 does not include numeric thresholds for grading of hypophosphatemia; all grades represent patients with lab value < Lower Limit of Normal (LLN).” | Regulatory label; not graded | SpringWorks Therapeutics (FDA label, DailyMed) 2026 |
| Dinutuximab beta: regular electrolyte monitoring (EU SmPC) “Regular monitoring of liver function and electrolytes is recommended.” | Regulatory label; not graded | European Medicines Agency (product information) 2026 |
| Abiraterone: correct hypokalaemia before and during treatment (US label) “Control hypertension and correct hypokalemia before and during treatment with ZYTIGA.” | Regulatory label; not graded | Janssen (FDA label, DailyMed) 2024 |
| Abiraterone: potassium level to consider maintaining in people with hypokalaemia (EU SmPC) “consider maintaining the patient’s potassium level at ≥ 4.0 mM” | Regulatory label; not graded | European Medicines Agency (product information) 2024 |
| Potassium management in people with cancer: all recommendations “all the recommendations about potassium disorders have level of evidence IV and grade of recommendation D” | level of evidence IV and grade of recommendation D | Sociedad Española de Oncología Médica (Clinical and Translational Oncology; De las Peñas et al.; two authors declare being scientific advisors of Otsuka, Spain) 2014 |
| Severe hypokalaemia (below 2.5 mmol/L): potassium intravenously, with a limit on the rate “In cases of severe hypokalemia (K+ <2.5 mmol/l), potassium is given intravenously, but the rate of potassium administration should not exceed 20 Eq/h (100–150 mEq/day).” | level of evidence IV and grade of recommendation D | Sociedad Española de Oncología Médica (Clinical and Translational Oncology; De las Peñas et al.; two authors declare being scientific advisors of Otsuka, Spain) 2014 |
| Oral potassium preferred outside critical situations “Oral supplements are safe and generally preferred to intravenous replacement in noncritical scenarios” | Conference report; not graded | KDIGO (Kidney International; Clase et al.) 2020 |
| Intravenous potassium chloride at up to 20 mmol an hour in severe hypokalaemia or when oral intake is not possible “Intravenous potassium chloride at a rate up to 20 mmol/h can be a safe alternative in persons with severe hypokalemia and when oral intake is not possible” | Conference report; not graded | KDIGO (Kidney International; Clase et al.) 2020 |
| Low magnesium to be addressed when correcting low potassium “Concomitant hypomagnesemia is likely underrecognized yet important to address when correcting hypokalemia” | Conference report; not graded | KDIGO (Kidney International; Clase et al.) 2020 |
| Rate of intravenous potassium (England) “The rate of IV potassium should not normally exceed 10mmol/hour. Administration rates above 20mmol/hour require cardiac monitoring due to the risk of arrhythmias.” | National guidance; not graded | NHS Specialist Pharmacy Service (England) 2024 |
| No national guideline for acute hypophosphataemia in the UK “There are no national guidelines for the treatment of acute hypophosphataemia and practice varies widely across hospital Trusts.” | Medicines information Q&A; not graded | UK Medicines Information (NHS), copy hosted by Gloucestershire Hospitals NHS Foundation Trust 2017 |
| Which low phosphate to treat: consensus across reviews and guidelines “the general consensus seems to be to treat severe or moderate symptomatic hypophosphatemia, with differing recommendations for dosing and monitoring” | Umbrella review; not graded | BMC Medicine (Netzer et al.; funded by the University of Bern and its hospital, with a Swiss National Foundation grant to one author, no competing interests declared) 2025 |
| Low phosphate in people with cancer: correct when first recognised “Hypophosphatemia in cancer patients should be corrected when it is first recognized and can be addressed by any member of the oncology team.” | Narrative review; not graded | Clinical Kidney Journal (Adhikari et al.; narrative review, no conflict of interest declared) 2021 |
| Low phosphate is not a reason to discontinue cancer therapy unless recurrent and life-threatening “hypophosphatemia, unless recurrent and life-threatening, should not be regarded as a reason to discontinue active cancer therapy” | Narrative review; not graded | Clinical Kidney Journal (Adhikari et al.; narrative review, no conflict of interest declared) 2021 |
| CTCAE hypokalaemia: Grade 3 is below 3.0 down to 2.5 mmol/L with hospitalisation indicated; Grade 4 is below 2.5 mmol/L with life-threatening consequences (the same in v5.0 and v6.0) | Severity scale; not a recommendation | US National Cancer Institute 2025 |
| CTCAE hypophosphataemia: Grade 2 is oral replacement therapy indicated; Grade 3 is severe or medically significant but not immediately life-threatening, with hospitalisation or prolongation of hospitalisation indicated; no numeric thresholds (the same in v5.0 and v6.0) | Severity scale; not a recommendation | US National Cancer Institute 2025 |
Shares Capillary leak syndrome on tagraxofusp, dinutuximab, aldesleukin and gemcitabine: monitoring and treatment, Tumour lysis syndrome: risk assessment, prophylaxis and treatment.
Shares Capillary leak syndrome on tagraxofusp, dinutuximab, aldesleukin and gemcitabine: monitoring and treatment, Diarrhoea from chemotherapy, targeted therapy and radiotherapy: grading, loperamide, octreotide and when to admit.
Shares CTCAE toxicity grading (grade 3-4 adverse events), Diarrhoea from chemotherapy, targeted therapy and radiotherapy: grading, loperamide, octreotide and when to admit.
Shares Capillary leak syndrome on tagraxofusp, dinutuximab, aldesleukin and gemcitabine: monitoring and treatment, CTCAE toxicity grading (grade 3-4 adverse events).
Shares CTCAE toxicity grading (grade 3-4 adverse events), Diarrhoea from chemotherapy, targeted therapy and radiotherapy: grading, loperamide, octreotide and when to admit.
Shares QT prolongation, QT prolongation on cancer medicines: ECG and blood salt monitoring, and when to pause or stop.